Guide
What isolated DHM, Hovenia extract trials, and a mixed-supplement cohort can tell us about the morning after drinking
6 min read
Randomized human evidence that isolated dihydromyricetin (DHM) improves next-day alcohol hangovers is not established in the research examined here. A systematic review searching through December 2025 found no clinical trials using isolated DHM; its human evidence came from two small Hovenia dulcis extract trials. A separate observational study examined a multi-ingredient supplement. These findings leave a DHM-specific hangover benefit, effective amount, and dosing schedule unestablished, including for Sauce Shield.
What should a randomized controlled trial of DHM measure?
If you want to know whether DHM helps the morning after drinking, the study needs to test that specific question. Finding DHM in an ingredient list or seeing alcohol mentioned in a paper is only the beginning.
A directly relevant randomized controlled trial in humans would need to report:
- Who participated: the adults studied, their eligibility criteria, and the alcohol-consumption conditions.
- What they received: isolated DHM, with its formulation and amount specified, rather than an extract or supplement containing several ingredients.
- How treatments were compared: random assignment to DHM and a comparison condition, with clear information about blinding and any placebo.
- When treatment happened: dosing in relation to drinking and the timing of the next-day assessment.
- What changed: measured hangover symptoms, with results showing the size and uncertainty of any difference between conditions.
Those details let you judge whether a result applies to your question. A randomized study measuring only a marker of alcohol metabolism would still leave next-day symptom relief unanswered. A symptom study using several ingredients would leave DHM's individual contribution unresolved.
What can the Hovenia extract trials tell us?
The systematic review included 22 studies spanning cell, animal, and clinical research. Its two clinical studies used Hovenia dulcis extracts. The review describes findings involving hangover severity and selected inflammatory markers, so the human research did reach symptom-related outcomes. It was not confined entirely to laboratory measurements.
The important limitation is the intervention. An extract containing DHM is a different preparation from isolated DHM. An outcome observed after taking that extract cannot be assigned to DHM alone without research that separates its contribution. The DHM ingredient guide provides broader background; this trial question depends on exactly what participants received.
A 2017 randomized, controlled crossover trial enrolled 26 male adults with heterozygous ALDH2 (reported age 23.7±0.3 years). Participants took 2460 mg of standardized Hovenia dulcis fruit extract or matched placebo together with 360 mL of Korean Soju (50 g alcohol), then crossed over to the other condition. Blood samples were collected at baseline and 1, 4, and 12 hours after treatment.
Blood alcohol, acetaldehyde, and total hangover scores peaked at 1 hour, with no difference between groups at that point. The trial abstract reports a significantly greater decline in hangover symptom scores with the extract than with placebo, but does not give individual timepoint effect estimates or a complete symptom-assessment schedule. That finding does not establish symptom relief at every timepoint or a general next-day benefit. The small, selected group of young men with heterozygous ALDH2 limits how broadly the result applies. The study tested Hovenia fruit extract, not isolated DHM or Sauce Shield, so its dose and timing cannot establish a DHM-specific dosing recommendation.
The review itself used a narrative synthesis rather than a meta-analysis and lacked a formal standardized risk-of-bias assessment. Its findings identify a clinical evidence gap; they do not provide a pooled estimate of how much isolated DHM changes next-day hangovers.
What did the mixed-supplement study measure?
The observational study of Cheers Restore did collect next-morning reports after alcohol consumption. It enrolled 90 healthy adults, with a mean age of 44.4 years; 56% were female. Participants contributed 2,958 morning surveys across three self-selected conditions: alcohol-only nights, nights involving Cheers Restore, and a non-drinking baseline.
The intervention was a commercially available DHM- and L-cysteine-based multi-ingredient supplement. The abstract does not specify its ingredient amounts or exact dosing schedule, so it cannot establish a particular amount of DHM or a before-drinking, bedtime, or next-morning protocol.
Participants rated energy, mental clarity, physical well-being, and sleep quality on a 1–10 scale. In this cohort, supplement use was associated with statistically significant improvements in all four ratings compared with alcohol-only nights. The reported standardized effect sizes were small, with Cohen's d ranging from 0.20 to 0.32.
These were subjective next-day well-being outcomes. The abstract does not report a symptom-by-symptom hangover assessment or establish effects on individual complaints such as headache or nausea. It also does not establish that DHM caused the reported differences.
The analysis accounted for drink count and used participant-level random intercepts. Here, random intercepts describes a statistical model for repeated observations from the same people. It does not mean participants were randomly assigned to take the supplement. Thousands of morning surveys also remain repeated reports from 90 adults, rather than thousands of independent participants.
Because participants selected their own conditions, differences between supplement nights and alcohol-only nights may remain beyond what the model accounted for. The authors call for a randomized, placebo-controlled trial to establish causality. Even a causal result for that complete formula would require additional work to identify DHM's contribution.
Do alcohol-metabolism or liver results answer a hangover question?
Next-day symptom ratings, alcohol-metabolism measurements, and liver-injury biomarkers answer different research questions. A finding in one category cannot supply a missing result in another.
The systematic review covered laboratory and animal outcomes involving oxidative stress, inflammation, liver-injury biomarkers such as AST and ALT, ethanol metabolism, and neurobehavioral measures. These findings belong to their specific experimental models. They do not establish that a person taking a DHM capsule after drinking will feel better the next morning.
The review also described ethanol-metabolism and neurobehavioral findings as inconsistent. That limits how confidently those findings can explain an expected human result. Neither a proposed mechanism nor an animal outcome establishes faster sobriety, a lower blood alcohol concentration, or a next-day hangover benefit in people taking Sauce Shield.
How does Sauce Shield compare with the studied products?
Sauce Shield is Hytz's alcohol-focused, multi-ingredient capsule product. Its ingredients include DHM, B vitamins, zinc, turmeric, ginger, ginseng, prickly pear, milk thistle, and berberine. That makes it relevant to someone comparing DHM-containing supplements, while also making the complete formulation important to the comparison.
Neither the Hovenia extract trials described in the review nor the Cheers Restore cohort evaluated Sauce Shield. Their findings therefore do not establish a Sauce Shield hangover outcome. Sharing an ingredient cannot establish equivalent results across different preparations, amounts, additional ingredients, or dosing schedules.
A product label can tell you what a formula contains and how its serving is defined. It cannot establish that the formula reproduces a study result. The Supplement Facts label guide can help with that comparison. There is no isolated-DHM randomized hangover result here against which to match a labeled amount, and these studies do not establish an optimal Sauce Shield dosing time.
For Hytz product testing information, see the lab results page. Testing for contaminants, including heavy metals, addresses different questions from a randomized trial measuring next-day symptoms. For a broader look at the category, the guide to comparing hangover pills covers the product-comparison questions beyond this narrowly defined human-trial evidence.